65,437 trials
Non Small Cell Lung Cancer
Primary: Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3 — 0.92; 0.92; 0.92; 0.96 mRNA relative values (ratio with GAPDH) — p=<0.001
Dental Caries
Primary: Minimum pH — 5.40; 5.48; 5.25; 5.70 pH — p=0.001
Hypertension
Primary: Change in Systolic Blood Pressure From Baseline of the Preceding Study — 148.8; 148.8; 148.8; -8.7 mmHg
Central Neuropathic Pain
Primary: Mean Pain Score at Endpoint as Measured by Daily Pain Rating Scale (DPRS) — 4.8; 5.0 scores on scale — p=0.578
Dyslipidemia
Primary: Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score — 0.75 Intraclass correlation coefficient
Infections, Papillomavirus
Primary: Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 1.0 International Unit Per Milliliter (IU/mL)…
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough FEV1 After 48 Weeks — 0.077; 0.105; -0.036 Litres — p=<0.0001
Hypercholesterolemia · Coronary Heart Disease · Atherosclerosis
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment — -59.7200; -63.4800; -55.2200; -57.4200 Percentage
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough FEV1 at Week 48, Full Analysis Set - Clinic Spirometry (FAS-PFT) — 0.097; 0.116; -0.046 Litres — p=<0.0001
Non-small Cell Lung Cancer
Primary: Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR]) — 0.182 proportion of responders
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001
Tinea Pedis
Primary: Therapeutic Cure - Superiority Analysis — 76; 108; 24 Participants — p=0.0127
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Neuralgia
Primary: Weekly Mean Pain Score at End of Treatment (Week 8) From Daily Pain Diary — 4.61; 5.23 score on a scale — p=0.010
Diabetic Neuropathy
Primary: Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator. — 11; 52; 74; 196 Participants